TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28077140

Group type: EXPERIMENTAL
Intervention: Indacaterol (IND) + Glycopyrronium (GLY)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Indacaterol (IND)
Number of subjects: 78
Study: 26025128

Group type: EXPERIMENTAL
Intervention: Oral corticosteroids (OCS) - short-term oral prednisone bursts during acute asthma exacerbations
Number of subjects: 489
Study: 23250820

Group type: EXPERIMENTAL
Intervention: LigaSure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional dissection techniques
Number of subjects: 0
Study: 21225278

Group type: EXPERIMENTAL
Intervention: Patients with PAH
Number of subjects: 25

Group type: COMPARATOR
Intervention: Patients with PAH (OS(-))
Number of subjects: 25

Group type: COMPARATOR
Intervention: OS(+) patients
Number of subjects: 25
Study: 19791639

Group type: EXPERIMENTAL
Intervention: Low autonomy (LA) instructional climate
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Mastery motivational climate (MMC) instructional climate
Number of subjects: 117

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 117
Study: 17645252

Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with functional training
Number of subjects: 90

Group type: COMPARATOR
Intervention: Electroacupuncture
Number of subjects: 90

Group type: COMPARATOR
Intervention: Functional training
Number of subjects: 90
Study: 14747807

Group type: EXPERIMENTAL
Intervention: Delayed-release acetaminophen preparation (75 mg/kg) with whole bowel irrigation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no whole bowel irrigation)
Number of subjects: 10
Study: 11878526

Group type: EXPERIMENTAL
Intervention: 2.5 ml of 7.5 mg ml(-1) ropivacaine (18.75 mg)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 2.5 ml of 10 mg ml(-1) ropivacaine (25 mg)
Number of subjects: 104
Study: 9492256

Group type: EXPERIMENTAL
Intervention: 400 mg of itraconazole 40‐mg/mL oral suspension
Number of subjects: 10

Group type: COMPARATOR
Intervention: Four 100‐mg itraconazole capsules
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hydroxyitraconazole from the suspension
Number of subjects: 10

Group type: COMPARATOR
Intervention: Hydroxyitraconazole from the capsules
Number of subjects: 10
Study: 7987084

Group type: EXPERIMENTAL
Intervention: Loop excision (n = 38)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Cold-knife conization (n = 52)
Number of subjects: 90
Study: 2839280

Group type: EXPERIMENTAL
Intervention: Adriamycin 60 to 75 mg/m2 at 3-week intervals
Number of subjects: 106

Group type: COMPARATOR
Intervention: No antitumor therapy
Number of subjects: 106
Study: 31856675

Group type: EXPERIMENTAL
Intervention: TIPP technique
Number of subjects: 300

Group type: COMPARATOR
Intervention: Lichtenstein technique
Number of subjects: 300

Group type: COMPARATOR
Intervention: Shouldice technique
Number of subjects: 300
Study: 31366355

Group type: EXPERIMENTAL
Intervention: Web-based, electronic health record (EHR)-linked clinical decision support (CDS) system for cancer prevention and screening recommendations.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Specialized training, pilot testing, implementation plans, and post-implementation efforts.
Number of subjects: 28
Study: 28385642

Group type: EXPERIMENTAL
Intervention: Mechanical CPR (LUCAS)
Number of subjects: 757

Group type: COMPARATOR
Intervention: Manual CPR
Number of subjects: 757
Study: 24814388

Group type: EXPERIMENTAL
Intervention: Mericitabine (1000 mg) and ritonavir-boosted danoprevir (100 mg/100 mg) plus ribavirin (1000/1200 mg/day) for 24 weeks
Number of subjects: 66

Group type: COMPARATOR
Intervention: Mericitabine (1000 mg) and ritonavir-boosted danoprevir (100 mg/100 mg) without ribavirin (Arm B) for 24 weeks
Number of subjects: 66
Study: 23911183

Group type: EXPERIMENTAL
Intervention: Sensor-augmented pump therapy with threshold suspend
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sensor-augmented pump therapy (control)
Number of subjects: 0
Study: 21744200

Group type: EXPERIMENTAL
Intervention: Handpiece removal of mini-implants
Number of subjects: 25

Group type: COMPARATOR
Intervention: Manual removal of mini-implants
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Local anesthetic injection
Number of subjects: 25

Group type: COMPARATOR
Intervention: No local anesthetic injection
Number of subjects: 25
Study: 18096918

Group type: EXPERIMENTAL
Intervention: CICS Provided
Number of subjects: 226

Group type: COMPARATOR
Intervention: No CICS Provided
Number of subjects: 226
Study: 16484892

Group type: EXPERIMENTAL
Intervention: Glibenclamide (20 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 14574783

Group type: EXPERIMENTAL
Intervention: High-dose paracetamol (6 g daily)
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2500
Study: 11086269

Group type: EXPERIMENTAL
Intervention: Non-directive counselling
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Cognitive-behaviour therapy
Number of subjects: 464

Group type: COMPARATOR
Intervention: Usual GP care
Number of subjects: 464
Study: 9411418

Group type: EXPERIMENTAL
Intervention: Diet only (25 kcal/kg b.w.)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Insulin therapy (mean daily dose 18 +/- 8 U)
Number of subjects: 42
Study: 1551536

Group type: EXPERIMENTAL
Intervention: Clonidine (150 micrograms single dose)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Clonidine (150 micrograms/day for 1 week)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Clonidine (150 micrograms single dose and 150 micrograms/day for 1 week)
Number of subjects: 17
Study: 2864845

Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 15

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 15
Study: 30266522

Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention (40 minutes, 3-5 times per week for 24 weeks)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 68
Study: 26659714

Group type: EXPERIMENTAL
Intervention: Pentacam HR measurements in early keratoconus (Krumeich stage 1 or 2)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Pentacam HR measurements in advanced keratoconus (Krumeich stage >2)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Keratometric measurements on Pentacam HR
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Increase in K1, K2 or Kmax of more than 1 dioptre in early keratoconus
Number of subjects: 96
Study: 25046070

Group type: EXPERIMENTAL
Intervention: Desloratadine (5 mg/d)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Desloratadine (5 mg) plus montelukast (10 mg)
Number of subjects: 40
Study: 22967772

Group type: EXPERIMENTAL
Intervention: Olanzapine treatment for 8 weeks
Number of subjects: 205
Study: 20603454

Group type: EXPERIMENTAL
Intervention: Early-onset conduct disorder (EO-CD)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Adolescence-onset conduct disorder (AO-CD)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 75
Study: 17393438

Group type: EXPERIMENTAL
Intervention: Gabapentin (1,200-2,400 mg/day)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 15741834

Group type: EXPERIMENTAL
Intervention: Secretion rate of s‐IgA
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: s‐IgA
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Incidence of URTI
Number of subjects: 100
Study: 12049678

Group type: EXPERIMENTAL
Intervention: Esmolol (24-hour infusion starting 6-18 hours after CABG at an average dose of 67 +/- 7 microg/kg/min)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Oral beta-blockers only (starting on postoperative day 1)
Number of subjects: 50
Study: 9528875

Group type: EXPERIMENTAL
Intervention: Three-film series (occipito mental, occipito mental 30 and lateral)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Two-film series (lateral excluded)
Number of subjects: 200
Study: 8535804

Group type: EXPERIMENTAL
Intervention: Axillary node sampling
Number of subjects: 417

Group type: COMPARATOR
Intervention: Axillary clearance
Number of subjects: 417
Study: 2200924

Group type: EXPERIMENTAL
Intervention: Benazepril (BNZ)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 4561679

Group type: EXPERIMENTAL
Intervention: Bromhexine (24 mg or 48 mg daily)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 31759092

Group type: EXPERIMENTAL
Intervention: Generativity writing condition (6-week intervention)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control writing condition (neutral, descriptive writing)
Number of subjects: 73
Study: 31240303

Group type: EXPERIMENTAL
Intervention: Protein supplementation (PRO group)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (CON group)
Number of subjects: 44
Study: 28266318

Group type: EXPERIMENTAL
Intervention: Intensive Short-Term Dynamic Psychotherapy (ISTDP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 60
Study: 26094782

Group type: EXPERIMENTAL
Intervention: 1-day workshop plus educational material
Number of subjects: 70

Group type: COMPARATOR
Intervention: Written educational material alone
Number of subjects: 70
Study: 23461482

Group type: EXPERIMENTAL
Intervention: Audiotape educational programme
Number of subjects: 70

Group type: COMPARATOR
Intervention: Routine training
Number of subjects: 70
Study: 22092124

Group type: EXPERIMENTAL
Intervention: Triple prophylaxis (dexamethasone 8 mg IV, ondansetron 4 mg IV, droperidol 0.625 mg IV)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Dexamethasone added to ondansetron and droperidol
Number of subjects: 157

Group type: COMPARATOR
Intervention: Ondansetron and droperidol (with or without dexamethasone)
Number of subjects: 157
Study: 20131551

Group type: EXPERIMENTAL
Intervention: Topical diltiazem hydrochloride ointment (2%)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Topical glyceryl trinitrate ointment (0.2%)
Number of subjects: 102
Study: 16340950

Group type: EXPERIMENTAL
Intervention: Iron plus iodine (190 mg iodine + 300 mg ferrous sulphate 5 times/week, n=24)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Iron (300 mg ferrous sulphate 5 times/week, n=23)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Iodine (190 mg iodine, n=25)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo (n=22)
Number of subjects: 103
Study: 14760043

Group type: EXPERIMENTAL
Intervention: Short standardized follow-up telephone call 1 week later
Number of subjects: 399

Group type: COMPARATOR
Intervention: Standard intervention (no telephone call)
Number of subjects: 399
Study: 10693639

Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2) 4 ng/kg per min for 6 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9121326

Group type: EXPERIMENTAL
Intervention: Rifampicin plus ofloxacin administered daily for 4 weeks
Number of subjects: 125
Study: 8457524

Group type: EXPERIMENTAL
Intervention: Palm oil diet
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 38
Study: 3721646

Group type: EXPERIMENTAL
Intervention: Salmon calcitonin 100 IU i.m. daily for 30 days
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 30138966

Group type: EXPERIMENTAL
Intervention: Adiponectin (20 μg/ml for 30 minutes)
Number of subjects: 0
Study: 30427152

Group type: EXPERIMENTAL
Intervention: Decrease of body temperature (till 35.9 °C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decrease of pH of venous blood (till 7.19)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decrease of ionized calcium content (till 0.32 mmole/l) in venous blood
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increase of lactate content (up to 4.1 mmole/l) in venous blood
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rise of activated partial thromboplastin time (up to 59 sec)
Number of subjects: 0
Study: 24415567

Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg/d
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg/d
Number of subjects: 161

Group type: COMPARATOR
Intervention: Historical control (pseudo‐placebo monotherapy)
Number of subjects: 161
Study: 22762977

Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural anesthesia (CSE)
Number of subjects: 50

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 50
Study: 20042202

Group type: EXPERIMENTAL
Intervention: Erythropoietin therapy
Number of subjects: 320

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 320
Study: 18354140

Group type: EXPERIMENTAL
Intervention: Arthroscopic acromioplasty with mini-open rotator cuff repair (scope mini-open)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open surgical repair
Number of subjects: 0
Study: 15842269

Group type: EXPERIMENTAL
Intervention: Coronally positioned flap alone (20 sites)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Coronally positioned flap with biodegradable membrane (20 sites)
Number of subjects: 20
Study: 12215986

Group type: EXPERIMENTAL
Intervention: Genioplasty
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Large advancements (>7 mm)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Small advancements (≤7 mm)
Number of subjects: 127

Group type: COMPARATOR
Intervention: No genioplasty
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Age (older subjects)
Number of subjects: 127
Study: 10512342

Group type: EXPERIMENTAL
Intervention: Eccentric kinetic chain exercise for 12 weeks
Number of subjects: 26
Study: 7853417

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide-based regimen with chest radiotherapy (n = 47)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Cyclophosphamide-based regimen without chest radiotherapy (n = 46)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Etoposide and cisplatin plus twice-daily chest radiotherapy (n = 54)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Standard-dose etoposide plus cisplatin (n = 46)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: High-dose etoposide plus cisplatin (n = 44)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Standard dose etoposide plus cisplatin for poor-risk patients (n = 25)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Overall survival evaluation based on BMI levels
Number of subjects: 262
Study: 1960557

Group type: EXPERIMENTAL
Intervention: Doxorubicin 60 mg/m2
Number of subjects: 141

Group type: COMPARATOR
Intervention: Epirubicin 90 mg/m2
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Doxorubicin
Number of subjects: 141

Group type: COMPARATOR
Intervention: Epirubicin
Number of subjects: 141
Study: 6758456

Group type: EXPERIMENTAL
Intervention: TEA for 24 hours
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: TEA plus general anesthesia with IPPV
Number of subjects: 98

Group type: COMPARATOR
Intervention: General anesthesia with IPPV but no TEA
Number of subjects: 98
Study: 31162017

Group type: EXPERIMENTAL
Intervention: Doxycycline 200 mg/day for 6 weeks
Number of subjects: 202

Group type: COMPARATOR
Intervention: Delayed treatment (6 months deferred)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Doxycycline treatment
Number of subjects: 202
Study: 29186908

Group type: EXPERIMENTAL
Intervention: High protein and high fiber diet (HPHFib)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Standard diet (StdD)
Number of subjects: 89
Study: 26552032

Group type: EXPERIMENTAL
Intervention: Stochastic leader gravitational search algorithm (SL‐GSA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard GSA (SGSA)
Number of subjects: 0
Study: 23924263

Group type: EXPERIMENTAL
Intervention: Passive arms (web access to facilitator training materials and toolkits without technical assistance)
Number of subjects: 7200

Group type: EXPERIMENTAL
Intervention: Passive arms (web access to facilitator training materials and toolkits with technical assistance)
Number of subjects: 7200

Group type: EXPERIMENTAL
Intervention: Active arms (in-person access to facilitator training materials and toolkits without technical assistance)
Number of subjects: 7200

Group type: EXPERIMENTAL
Intervention: Active arms (in-person access to facilitator training materials and toolkits with technical assistance)
Number of subjects: 7200

Group type: COMPARATOR
Intervention: N/A (control group not explicitly mentioned)
Number of subjects: 7200
Study: 21574777

Group type: EXPERIMENTAL
Intervention: Creatine (20 g·day(‐1) for 1 week and 5 g·day(‐1) thereafter)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 19292064

Group type: EXPERIMENTAL
Intervention: MTX/Isoniazid (INH)
Number of subjects: 201

Group type: COMPARATOR
Intervention: MTX alone
Number of subjects: 201
Study: 17000348

Group type: EXPERIMENTAL
Intervention: Psychological factors (arousal and valence)
Number of subjects: 525
Study: 15577627

Group type: EXPERIMENTAL
Intervention: Behavioural intervention activities (attendance at meetings, videos, dramas, interactions with community educators)
Number of subjects: 3394

Group type: COMPARATOR
Intervention: No intervention (comparison communities)
Number of subjects: 3394
Study: 11378339

Group type: EXPERIMENTAL
Intervention: Chemotherapy (doxorubicin 50 mg/m² i.v. bolus and ifosfamide 5 g/m² 24 h infusion)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Chemotherapy (doxorubicin and ifosfamide)
Number of subjects: 134
Study: 9294274

Group type: EXPERIMENTAL
Intervention: Diagnostic laparoscopy
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control group (no laparoscopy)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Postmenopausal women
Number of subjects: 161

Group type: COMPARATOR
Intervention: Male adults
Number of subjects: 161
Study: 8357473

Group type: EXPERIMENTAL
Intervention: Sublingual specific immunotherapy with purified and standardised allergen (Stallergenes '5-grass pollen')
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 3511392

Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg 5 X in 30 h)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31884895

Group type: EXPERIMENTAL
Intervention: Sleep Hygiene Protocol (SHP)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 22
Study: 29982277

Group type: COMPARATOR
Intervention: Casein protein-based (CP) meals
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Pea protein-based (PP) meals
Number of subjects: 37

Group type: COMPARATOR
Intervention: CP meals
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: PP meals
Number of subjects: 37
Study: 27788184

Group type: EXPERIMENTAL
Intervention: Revised Illness Perception Questionnaire (IPQ‐R)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psoriasis Life Stress Inventory (PLSI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: WHOQOL‐Physical
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: WHOQOL‐Psychological
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: WHOQOL‐Social
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: WHOQOL‐Environmental
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation between emotional representations associated with ZCL and loss of self-esteem
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation between education level and cognitive/emotional representation in IPQ‐R
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation between rejection experiences and age
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation between anticipation and avoidance of stress and age
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation between perceived quality of social life and knowledge about ZCL
Number of subjects: 0
Study: 23579066

Group type: EXPERIMENTAL
Intervention: Multifactorial, individualized 12-month falls prevention programme
Number of subjects: 1314
Study: 22837545

Group type: EXPERIMENTAL
Intervention: Aerobic physical conditioning with moderate intensity
Number of subjects: 42

Group type: COMPARATOR
Intervention: Daily life activities (Control)
Number of subjects: 42
Study: 20484474

Group type: EXPERIMENTAL
Intervention: GHRH+Arg test
Number of subjects: 69

Group type: COMPARATOR
Intervention: ITT test
Number of subjects: 69
Study: 18492001

Group type: EXPERIMENTAL
Intervention: Progressive resistance exercise program (3 times a week for 8 weeks)
Number of subjects: 32
Study: 16163677

Group type: EXPERIMENTAL
Intervention: Revised questionnaire after initial comments from first three groups
Number of subjects: 31

Group type: COMPARATOR
Intervention: Initial questionnaire before revisions
Number of subjects: 31
Study: 12969045

Group type: EXPERIMENTAL
Intervention: OAA leaflet 'Pain Relief in Labour' (Intervention group)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard booking information (Control group)
Number of subjects: 76
Study: 11130159

Group type: EXPERIMENTAL
Intervention: Michigan Alcoholism Screening Test (MAST)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: CAGE
Number of subjects: 135
Study: 8806373

Group type: EXPERIMENTAL
Intervention: Bathers exposed to fecal streptococci
Number of subjects: 1273

Group type: EXPERIMENTAL
Intervention: Bathers exposed to fecal coliform
Number of subjects: 1273

Group type: EXPERIMENTAL
Intervention: Bathers
Number of subjects: 1273

Group type: COMPARATOR
Intervention: Nonbathers
Number of subjects: 1273
Study: 1628583

Group type: EXPERIMENTAL
Intervention: Progressive Relaxation Training (PRT, n = 13)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Quiet Sitting (QS, n = 11)
Number of subjects: 24
Study: 6480200

Group type: EXPERIMENTAL
Intervention: Concentric exercise
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Number of subjects: 8
Study: 31527899

Group type: EXPERIMENTAL
Intervention: artesunate‐amodiaquine (ASAQ)
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: artemether‐lumefantrine (AL)
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: quinine+clindamycin (QnC)
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: postRCT1
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: postRCT2
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: postRCT3
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: preRCT
Number of subjects: 865
Study: 29540336

Group type: EXPERIMENTAL
Intervention: Ilaparazole 10 mg QD
Number of subjects: 537

Group type: COMPARATOR
Intervention: Esomeprazole 40 mg QD
Number of subjects: 537
Study: 27041672

Group type: EXPERIMENTAL
Intervention: FEC-Docetaxel (FEC-D)
Number of subjects: 66

Group type: COMPARATOR
Intervention: TCx6 (TC6)
Number of subjects: 66